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InhibitionAmyloid ﬁbrils have been associated with at least 25 different degenerative diseases. The 51-residue
polypeptide hormone insulin, which is associated with type II diabetes, has been shown to self-assemble to
form amyloid ﬁbrils in vitro. With bovine insulin as a model, the research presented here explores the
effects of two amphiphilic surfactants (1,2-dihexanoyl-sn-glycero-3-phosphocholine (di-C7-PC) and 1,2-
diheptanoyl-sn-glycero-3-phosphocholine (di-C7-PC)) on the in vitro ﬁbrillation process of bovine insulin at
pH 2.0 and 55 °C. We demonstrated that insulin ﬁbrillation may be inhibited by both surfactants in a dose-
dependent fashion. The best inhibition of ﬁbril formation is observed when insulin is incubated with 4 mM
di-C7-PC. Moreover, the addition of either surfactant at the concentrations studied attenuated insulin ﬁbril-
induced cytotoxicity in both PC12 and SH-SY5Y cell lines. The results from this work may contribute to the
understanding of the molecular factors affecting amyloid ﬁbrillation and the molecular mechanism(s) of the
interactions between the membrane and amyloid proteins.Engineering, National Taiwan
0617. Tel.: +886 2 3366 5870;
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Protein aggregation is a prevalent phenomenon encountered in
the medical ﬁeld, and the resulting protein aggregates can have
serious deleterious effects in vivo. Protein aggregates in general can be
divided into two classes: amyloid ﬁbrils, which have highly ordered
structures, and irregular or amorphous aggregates, which have no
long-range structure. The structure of amyloid ﬁbrils is thought to
exhibit several speciﬁc tinctorial and physicochemical features (e.g., a
β-sheet-rich secondary structure, ﬁbrillar morphology, birefringence
to polarized light, insolubility in most solvents, and protease
resistance) [1–3]. To date, the accumulation of protein amyloid ﬁbrils
has been associated with more than 25 diverse, debilitating, and
incurable human disorders, which are either neuropathic or non-
neuropathic and are collectively termed the conformational diseases.
These diseases include hemodialysis amyloidosis, type II diabetes,
Parkinson's disease, Huntington's disease, and Alzheimer's disease
[1,3,4]. These diseases have distinct clinical, pathological, and
biochemical characteristics, and their corresponding precursor pro-
teins have unrelated functions and do not share any signiﬁcant
sequence homology. Due to the morphological similarities between
ﬁbrils that are formed by many different protein building blocks, it
has been hypothesized that different proteins follow similar ﬁbrilformation pathways [1,5]. Nevertheless, the precise molecular
mechanisms of amyloid ﬁbrillation remain to be fully elucidated
[1,3,4].
A growing body of evidence suggests that amyloid ﬁbril formation
is not limited to protein sequences that may be associated with
amyloidogenic diseases. Several non-pathogenic proteins have been
induced in vitro to self-assemble into amyloid ﬁbrils upon destabili-
zation of their native state [6,7]. The aforementioned observations
have led to the hypothesis that the ability to form amyloid aggregates
is a basic generic property of polypeptide backbones and that most
or indeed all peptides/proteins have the potential to form such
structures in vitro under certain conditions [1,8].
Extensive efforts have been directed toward screening or devel-
oping anti-amyloidogenic or anti-aggregating agents as a means
of treating amyloidoses [9,10]. A variety of natural or synthesized
molecules/compounds have been reported to retard or prevent ﬁbril
formation both in vitro and in vivo [10,11]. While amyloidoses have
been the center of intense research efforts, no cure is currently avail-
able for these diseases. Inhibiting the production of pathogenic ﬁ-
brillar/aggregated conformers or capturing these species has
emerged as a potential approach to tackling amyloidoses.
Bovine insulin is a 51-amino-acid protein hormone involved
in regulating glucose metabolism. It is used to treat diabetes. Its
monomeric form consists of a 21-residue A chain containing one
disulﬁde bond and a 30-residue B chain, which are linked together by
a pair of inter-chain disulﬁde bridges [12]. Structurally, insulin
primarily adopts a helical conformation at pH 2.0 (∼44% α-helix;
∼9% β-sheet, ∼30% random coil, and ∼19% turn) [13] and exists as a
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mers, in a solution the composition of which is strongly depending
on the environmental conditions [13,14]. Bovine insulin is one of
the best-characterized proteins, and its three-dimensional structure,
folding–unfolding mechanism, unfolding intermediates, and stability
information have been extensively investigated [15–17]. Moreover,
bovine insulin is structurally homologous to human insulin (they
differ by only three amino acids), which has been associated with the
clinical syndrome injection-localized amyloidosis [18–20]. Therefore,
bovine insulin serves as an excellent model system with which to
study in vitro ﬁbrillation-relevant phenomena.
The amphiphilic surfactants, di-C7-PC and di-C7-PC, that we used
in this study belong to the subclasses of diacyl glycerophosphocholine
(diacyl-GPC) or lecithin, which is one of the predominant phospho-
lipids or lipid components present in the human body (e.g., gray
matter of the brain, cell membrane of erythrocytes, human plasma,
and membrane of blood platelets) [21–24]. Findings from our pre-
vious work suggest that di-C6-PC and di-C7-PC may prevent the
ﬁbrillation of β-amyloid [11]. As a result, we were interested to study
whether these amphiphilic surfactants inﬂuenced the in vitro acid-
induced ﬁbrillation and cytotoxicity of bovine insulin. In the current
work, using a number of spectroscopic techniques and transmission
electron microscopy (TEM), we ﬁrst demonstrate that both amphi-
philic surfactants exhibited anti-aggregating and anti-amyloidogenic
activities, which are dependent upon their concentrations and
incubation times. Moreover, our results indicate that 4 mM surfactant
di-C7-PC produces the best inhibition of ﬁbrillation of bovine insulin.
Next, we ﬁnd that the amyloid ﬁbrillar species of bovine insulin
formed at acidic pH (pH 2.0) and elevated temperature (55 °C) elicit
cellular cytotoxic responses in the PC12 and SH-SY5Y cell lines using
the MTT reduction assay. Finally, we show that both surfactants at the
concentrations tested (0.5–4 mM) are able to attenuate the decline in
cell viability induced by insulin ﬁbrils in both cell lines. In addition, at
the same concentrations of surfactant, the exposure of di-C7-PC leads
to lower levels of ﬁbrillation and cytotoxicity associated with bovine
insulin ﬁbrils as compared with that of di-C6-PC. We believe that the
results reported here could have implications for the understanding of
the role of membranes or membrane mimetic conditions in amyloid
ﬁbril formation and the interacting mechanism(s) between the
amyloid proteins and lipid membranes or surfactant molecules.
2. Materials and methods
2.1. Chemicals
Zinc-free bovine pancreatic insulin (BPI), purchased from Sigma
(USA), was refrigerated upon receipt and used without further
puriﬁcation. Sodium chloride and potassium chloride were purchased
from Nacalai Tesque, Inc. (Japan). The amphiphilic surfactants 1,2-
dihexanoyl-sn-glycero-3-phosphocholine (di-C6-PC) and 1,2-dihep-
tanoyl-sn-glycero-3-phosphocholine (di-C7-PC) were purchased
from Avanti Polar Lipids, Inc. (USA). All other chemicals, unless
otherwise speciﬁed, were of analytical grade and purchased from
Sigma (USA).
2.2. In vitro insulin ﬁbril formation
Sample solutions with 100 μM BPI were prepared by dissolving
insulin powder in an aqueous HCl solution (pH 2.0) with 0.01% (w/v)
sodium azide. The BPI solutions were ﬁrst mixed via vortexing and
then incubated at 55 °C to induce ﬁbril formation.
2.3. Thioﬂavin T ﬂuorescence (ThT) assay
A stock solution of ThT was prepared in de-ionized water, and the
concentration was determined spectrophotometrically using a molarextinction coefﬁcient at 416 nm of 26,600 M−1 cm−1 [25]. Insulin
samples co-incubated with various concentrations of di-C6-PC and di-
C7-PC (0, 0.5, 1, 2, and 4 mM) were diluted 25-fold with ThT solution
(20 μM), and ﬂuorescence intensities were measured by exciting
samples at 440 nm and recording emissions at 485 nm with a Cary
Eclipse Fluorescence Spectrophotometer (Varian, USA). The data from
ThT ﬂuorescence measurements were ﬁtted to a sigmoidal curve
described by the following equation [14]:
F = Fi + mit +
Ff + mf t
1 + e−½ðt−toÞ=τ
ð1Þ
where F is the ﬂuorescence intensity at time t, t is the incubation time,
to is the time to reach 50% of maximal ﬂuorescence, and (Fi+mit) and
(Ff+mft) represent the initial baselines corresponding to the
induction period and the ﬁnal plateau line, respectively. The values
of the three parameters mi, mf, and τ were obtained by nonlinear
regression. The apparent rate constant for ﬁbril growth was found to
be 1/τ, and the lag time was found to equal to – 2τ.
2.4. Congo red binding assay
An aliquot (160 μl) of the BPI solutions or control buffers was
added to 1640 μl of 20 μM Congo red solution in PBS and incubated at
room temperature for 30 min before measurement. The spectra of
samples were recorded from 400 to 700 nm using a SPEKOL 1300 UV-
Visible Spectrophotometer (Analytic Jena, Japan). The concentration
of ﬁbrillar species in the BPI solutions was determined using the
following equation:
½fibrillar BPI = A540 = 25;295 − A477 = 46;306 ð2Þ
where [ﬁbrillar BPI] is the concentration of BPI ﬁbrils, and A540 and
A477 are the Congo red absorbance of the peptide sample at 540 and
477 nm, respectively [26]. The relative ﬁbril formation was deter-
mined from the ratio of the ﬁbril concentration in the presence of
surfactant to the ﬁbril concentration of pure BPI.
2.5. Circular dichroism spectroscopy
Circular dichroism (CD) spectra were recorded on a J-815
spectrometer (JASCO, Japan) at 25 °C using a bandwidth of 1.0 nm, a
step interval of 0.1 nm, a scanning speed of 50 nm/min, a resolution of
0.1 nm, and an averaging time of 2 s. A 0.2-cm quartz cell was used for
far-UV (190–260 nm) measurements. Three scans of duplicate
samples were measured and averaged. Control buffer scans were
run in duplicate, averaged, and then subtracted from the sample
spectra. The secondary structure contents (α-helix, β-sheet, turn, and
random coil) of the samples were estimated using the CDSSTR
algorithm with reference set 7 available from the DICROWEB website
[27].
2.6. Transmission electron microscopy
A 10-μl sample was placed on a carbon-stabilized, formvar-coated
grid. Grids were negatively stained with 2% (w/v) aqueous uranyl
acetate (Electron Microscopy Sciences, Hatﬁeld, PA, USA) and then
examined and photographed under a Hitachi H-7650 transmission
electron microscope with a Gantan model 782 CCD Camera (Tokyo,
Japan) at an accelerating voltage of 100 kV.
2.7. Cell culture
Rat pheochromocytoma PC12 cells (ATCC, Rockville, MD) were
cultured in DMEM medium supplemented with 10% (v/v) horse
serum, 5% (v/v) fetal bovine serum (FBS), and 100 U/ml penicillin in
Fig. 1. Amyloid ﬁbrillation kinetics of bovine insulin. The extent of ﬁbril formation was
monitored via Congo red absorption spectra as a function of incubation time. Bovine
insulin samples were dissolved in hydrochloric acid (pH 2.0) and incubated at 55 °C
during the course of experiment. The extent of ﬁbril formation was also monitored via
ThT ﬂuorescence as a function of incubation time and is shown in the inset. Data represent
the mean ThT ﬂuorescence measurement of at least 5 independent experiments (n≥5).
Error bars represent the standard deviation (SD) of the ﬂuorescence measurements.
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cultured in humidiﬁed 5% (v/v) CO2/air at 37 °C in DMEM-F12
medium supplemented with 10% (v/v) FBS and 100 U/ml penicillin.
Cells were plated at a density of 5×104 cells/ml in 96-well plates and
the BPI sample solution was added to the cells 24 h after plating.
2.8. MTT reduction assay
The cell viabilities of PC12 and SH-SY5Y were measured using the
3,(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT)
reduction assay. Viable cells reduce the MTT to form blue formazan
crystals, and inhibition of this reaction is indicative of cellular redox
changes that could result in toxicity [28]. For the MTT reduction
assays, stock sample solutions of BPI with various concentrations of
di-C6-PC and di-C7-PC were diluted to 100 μM with sterile DMEM/
DMEM-F12 medium. The diluted samples were added to the PC12/
SH-SY5Y cells in the 96-well plates from which the medium had been
removed.
The BPI sample solutions were incubated with PC12/SH-SY5Y cells
for 24 h, and MTT reduction was assessed. MTT was added to the
culture medium to yield a ﬁnal concentration of 0.5 mg/ml. The cells
were allowed to incubate with the MTT for 4 h in a CO2 incubator;
then 100 μl of a 5:2:3N,N-dimethylforamide (DMF):sodium dodecyl
sulfate (SDS):water solution (pH 4.7) was added to dissolve the forma-
zan crystals. After 18 h of incubation in a humidiﬁed CO2 incubator, the
absorbance at 585 nmwas read using a μQuant Microplate reader (Bio-
Tek Instruments, VT, USA). Cell viability was reported relative to
control cells that were not exposed to the BPI ﬁbril solutions.
2.9. Statistical analysis
All data are expressed as means±standard deviation (SD) for n
independent determinations. The signiﬁcance of the results was
determined with Student's t-test given n independent measurements,
where n is speciﬁed in the ﬁgure legend. Unless otherwise indicated,
signiﬁcance was determined as pb0.001.
3. Results
3.1. Kinetics of amyloid ﬁbrillation of BPI
Congo red binding was used as an indicator of extended β-pleated
sheet structures and BPI aggregation. We show in Fig. 1 that insulin by
itself signiﬁcantly bound Congo red and shifted the spectral properties
of the dye upon binding. An increase in Congo red absorption
accompanied by a red shift of the absorbance maximumwas apparent
upon incubation. As a complementary evaluation of amyloid ﬁbril
formation, the temporal evolution of ThT ﬂuorescence intensity was
monitored during incubation of BPI. ThT is thought to rapidly interact
with amyloid ﬁbrils in a speciﬁc manner, and the protein sequence
exerts a negligible effect on the binding of ThT. The increase in ThT
ﬂuorescence intensity has been widely used as an indicator of the
degree of amyloid ﬁbrillation [29]. As depicted in the inset of Fig. 1, the
ThT ﬂuorescence intensity of BPI alone (the control) increased and
reached a maximum at ∼320 h.
3.2. Effects of di-C6-PC and di-C7-PC on BPI amyloid ﬁbril formation
The effects of two surfactants, di-C6-PC and di-C7-PC, on the
amyloid ﬁbrillation of insulin were ﬁrst examined via ThT ﬂuores-
cence measurements. In Fig. 2A and B, the ThT ﬂuorescence of insulin
by itself increased dramatically in the ﬁrst 200 h and then reached a
ﬂuorescence plateau. In Fig. 2A and B, our results revealed that the
reduction level of insulin ﬁbrillation was dependent upon the
surfactant concentrations tested (0.5, 1.0, 2.0, and 4.0 mM). For
instance, after incubation for 320 h, the percentages of the maximumThT ﬂuorescence intensity of BPI samples incubated with 0.5, 1.0, 2.0,
and 4.0 mM di-C6-PC were 65.2±4.0%, 63.9±3.7%, 65.9±3.9%, and
42.2±3.6%, respectively, and with 0.5, 1.0, 2.0, and 4.0 mM di-C7-PC
were 82.2±4.2%, 25.9±5.9%, 32.0±9.0%, and 16.7±0.6%, respec-
tively (the percentage of the maximum ThT ﬂuorescence intensity of
BPI by itself = 100%). Notably, we found that neither surfactant by
itself quenched ThT ﬂuorescence at the concentrations examined in
this study. Therefore, the reduction in ThT ﬂuorescence observed in
the BPI samples could be attributed to attenuation of ﬁbrillation by the
addition of surfactant. As shown by the Congo red binding results in
the insets of Fig. 2A and B, the attenuated BPI ﬁbrillation due to
addition of either surfactant was positively correlated with the
surfactant concentration, analogous to the ThT ﬂuorescence emission
results. The surfactants by themselves did not alter the Congo red
binding absorbance.
The kinetic proﬁles of amyloid ﬁbrillation observed for BPI samples
prepared at pH 2.0 and 55 °C were indicative of a nucleation-
dependent polymerization mechanism [14,30]. To quantitatively
compare the extents of ﬁbrillation of BPI samples with the various
surfactant concentrations, a sigmoidal curve (the ﬁtting equation is
described in the Materials and methods section) was used to ﬁt the
data obtained from the ThT binding; the growth rate constant and the
lag time parameters were determined and listed in Table 1. It was
apparent that the presence of surfactant higher than 0.5 mM resulted
in a slower growth rate and a longer lag period as compared to the
control. Moreover, much longer lag phase periods were found in BPI
samples that contain di-C7-PC relative to those with the same
concentrations of di-C6-PC. However, except for the surfactant
concentration of 0.5 mM, a similar growth rate constant was observed
with di-C6-PC or di-C7-PC at the same concentration. Our data also
showed that di-C7-PC-containing BPI sample had a signiﬁcantly
smaller ﬁnal ThT ﬂuorescence intensity than that of di-C6-PC-
containing BPI samples in the surfactant concentration range of 1–
4 mM, implying that considerably smaller amount of ﬁbrils was
present in BPI samples with di-C7-PC as compared with those with di-
C6-PC.
Fig. 2. Effects of amphiphilic surfactants on the kinetics of amyloid ﬁbrillation of bovine
insulin (A) di-C6-PC and (B) di-C7-PC. Bovine insulin samples were dissolved in
hydrochloric acid (pH 2.0) and incubated at 55 °C during the course of experiment. The
extent of ﬁbril formation of bovine insulin was estimated via Congo red binding (inset)
and ThT ﬂuorescence as a function of incubation time. The relative ThT ﬂuorescence
intensity was determined by the ratio of ThT ﬂuorescence of the surfactant-containing
sample to that of the control at 320 h (the maximum ThT ﬂuorescence intensity). The
relative ﬁbril formation measured by Congo red was reported as the ratio of ﬁbrillar
insulin concentration of surfactant-insulin sample to pure ﬁbrillar insulin concentra-
tion. The ﬁbrillar insulin concentration was determined by Eq. (2) as described in the
Materials andmethods section. Data represent themean value of at least 5 independent
experiments (n≥5). Error bars represent the standard deviation (SD) of the
measurement.
Table 1
Calculated kinetic parameters for the amyloid ﬁbrillation from bovine insulin with
various concentrations of amphiphilic surfactants in the buffers.
Lag
timea
(h)
Lag
time
ratiob
Change
in lag
time (h)c
Growth
rate
constanta
(h−1)
Growth
rate
constant
ratiod
Final ThT
ﬂuorescence
intensity
Insulin 117.59 1.00 – 0.052 1.00 100
di-C6-PC 0.5 mM 136.77 1.16 19.18 0.036 0.69 65.20
1 mM 148.78 1.27 31.19 0.039 0.75 63.88
2 mM 152.77 1.30 35.18 0.043 0.83 65.89
4 mM 156.14 1.33 38.55 0.019 0.37 42.16
di-C7-PC 0.5 mM 138.15 1.17 20.56 0.052 1.00 82.17
1 mM 153.31 1.30 35.72 0.040 0.77 25.87
2 mM 163.99 1.39 46.40 0.042 0.81 32.03
4 mM 186.42 1.59 68.83 0.020 0.39 16.69
a Lag times and growth rate constants were determined by to and τ, the parameters
obtained from the nonlinear least square analysis using the equation listed in the
Materials and methods section.
b Lag time ratio is the ratio between the lag time for BPI with di-C6-PC or di-C7-PC
and that for BPI alone.
c Change in lag time is the difference between the measured lag time and that for
insulin alone (∼117.59 h).
d Growth rate constant ratio is the ratio between the growth rate constant for BPI
with di-C6-PC or di-C7-PC and that for BPI alone.
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The morphology of the BPI samples treated with various con-
centrations of either surfactant was analyzed by transmission electron
microscopy (TEM). Fig. 3A, B, and C displays representative micro-
graphs of BPI alone, BPI with 4 mM di-C6-PC, and BPI with 4 mM di-
C7-PC, respectively, after 320 h of incubation. It is apparent that the
control (insulin alone) contained a high density of needle-like species
reminiscent of typical amyloid ﬁbrils of ∼10 nm in diameter and
several μm in length (see Fig. 3A). Conversely, exposure of BPI to
either surfactant at 4 mM resulted in an attenuation of insulin
ﬁbrillation as depicted in Fig. 3B and C. In addition, the number of
ﬁbrils decreased with increasing concentrations of either surfactant.
According to our preceding ThT ﬂuorescence, Congo red binding, and
TEM results, we conclude that the presence of either di-C6-PC or di-
C7-PC leads to bona ﬁde prevention of ﬁbrillation. Furthermore, as
revealed by the ThT ﬂuorescence and Congo red binding results
(shown in Fig. 2A and B), di-C7-PC at 4 mM exhibited the optimal
inhibitory activity as compared to the other conditions examined.
3.4. Inﬂuence of di-C6-PC and di-C7-PC on BPI secondary structure
CD absorption spectroscopy was utilized to explore the inﬂuence
of di-C6-PC and di-C7-PC on the conformation of insulin. We show in
Fig. 4A and B that, at the beginning of the experiment, the far-UV CD
spectra of all BPI samples (with or without surfactant) displayed
similar spectra with intense maxima at ∼197–199 nm, shoulders at
∼225 nm, and absorption minima at ∼208 nm, which is characteristic
of an α-helix-rich conformation (∼38% α-helix, ∼16% β-sheet, ∼16%
turn, and ∼30% unordered). When the incubation time increased (for
instance, 320 h), BPI alone exhibited a structural transition, resulting
in a prominent alteration in the relative structural proportions. The
spectrum at 320 h exhibited a substantially different shape in which a
pronounced absorption minimum at ∼218 nm was observed, clearly
demonstrating a characteristic pattern of β-sheet conformation (∼7%
α-helix, ∼41% β-sheet, ∼19% turn, and ∼33% unordered; far-UV
CD spectra are shown in Fig. 4C and D). However, after 320 h of in-
cubation, the addition of di-C6-PC or di-C7-PC to BPI resulted in
different structural transitions compared to the controls (see Fig. 4C
and D). In addition, the changes in the CD signal given the presence of
surfactants suggested a concentration-dependent behavior. To better
Fig. 3. Negative staining transmission electron micrographs of bovine insulin ﬁbrils pre-
pared at pH 2.0 and incubated for 320 h in (A) bovine insulin alone, (B) bovine insulin and
4 mMdi-C6-PC, and (C) bovine insulin and 4 mMdi-C7-PC. The scale bar represents 0.2 μm.
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obtained at 0 and 320 h were further de-convoluted using the
software available from the DICROWEB website [27] and the results
are listed in Table 2. As expected, the β-sheet content of BPI alone
increased with time from ∼16% at 0 h to ∼41% at 320 h, and this
enhancement predominantly came from the decrease in α-helix
content. Upon prolonged incubation (e.g., 320 h), the addition of
surfactant induced an elevation in the unordered fraction and this
apparent increase seemed to be negatively correlated with the
concentration of surfactant. For the same incubation duration, the
β-sheet contents of the BPI samples containing various concentrations
of surfactants were markedly lower than those of the control. As
illustrated in Table 2, the β-sheet contents of all of the BPI samples at
320 h showed the following order: BPI alone N BPI with 0.5 mMdi-C7-
PC N BPI with 0.5 mM di-C6-PC≈ BPI with 1 mM di-C6-PC≈ BPI with
2 mM di-C6-PC N BPI with 4 mM di-C6-PC≈ BPI with 1 mM di-C7-PC
≈ BPI with 2 mM di-C7-PC N BPI with 4 mM di-C7-PC. Moreover, little
difference in the relative proportions of secondary structure elements
was detected between the 4 mM di-C7-PC-containing BPI samples at
0 and 320 h. The lowest level of β-sheet content in solution was
observed in the BPI sample with 4 mM di-C7-PC, suggesting that
4 mM di-C7-PC exhibited the strongest suppressing activity against
β-sheet formation and BPI ﬁbrillation/aggregation among the con-
ditions tested. This ﬁnding is consistent with our preceding ThT
ﬂuorescence measurements.
3.5. Effects of di-C6-PC and di-C7-PC on ﬁbrillar BPI-induced cytotoxicity
It is widely, but not universally, believed that aggregated/ﬁbrillar
amyloid proteins are toxic to neurons and neuron-like cells [31–34].
We were therefore interested in determining whether BPI ﬁbrillar
species prepared at pH 2.0 and 55 °C would be cytotoxic to human
neuroblastoma SH-SY5Y cells and rat pheochromocytoma PC12 cells
using the MTT reduction assay. The ability of cells to reduce the
metabolic dye MTT to a blue formazan product was used to measure
cell viability. The data are reported as the percentage of MTT reduced
by the cells treated with the insulin samples relative to MTT reduced
by untreated cells. Fig. 5A shows the effect of various concentrations
of BPI ﬁbrils on cell viability (or the percentage of MTT reduction).
Evidently, the percentage of MTT reduction or cell viability was
negatively correlated with the concentration of BPI ﬁbrils added.
Addition to BPI ﬁbrillar species, which were formed by 320-
h incubation, to the cell medium resulted in decreased MTT reduction
in both PC12 and SH-SY5Y cells. When the BPI concentration was
higher than 5 μM, this decrease was highly statistically signiﬁcant
(pb0.001) with respect to the controls, which involved incubating the
same cells with buffer solutions in the absence of protein. We show in
Fig. 5B that 24-h exposure to 100 μM320-h aged BPI ﬁbril, whichwere
shown to have a high β-sheet content (∼41%), to bind Congo red with
a high ﬁbrillar BPI concentration, and to emit high level of ThT
ﬂuorescence, signiﬁcantly decreased the observed MTT reduction
levels to 44.63% (pb0.001) and 51.45% (pb0.001) of the control levels
for PC12 and SH-SY5Y cells, respectively. These results indicate that a
substantial loss in cell survival occurred when cells were treated with
100 μM insulin ﬁbrils.
Our preceding results indicate that the addition of di-C6-PC or di-
C7-PC gives rise to a decrease in the aggregative or ﬁbrillogenic
propensity of BPI. To test whether both amphiphilic surfactants would
affect the biological effects of insulin ﬁbrils, we next investigated the
ability of di-C6-PC and di-C7-PC to attenuate the cytotoxicity induced
by BPI ﬁbrils. We found that co-incubation of 100 μM insulin with
varying concentrations of di-C6-PC or di-C7-PC (0.5–4 mM) resulted
in a dose-dependent decrease in cell death. As shown in Fig. 5B, the
cell viability of PC12 cells was increased from44.62±4.95% to 68.33±
2.89% with 0 to 0.5 mM di-C6-PC, whereas no obvious change in cell
viability (average cell viability of ∼69.27±1.03%) was observed
Fig. 4. Representative far-UV CD spectra of bovine serum insulin in the presence of various concentrations of amphiphilic surfactants at 0 h (A: di-C6-PC, B: di-C7-PC) and 320 h
(C: di-C6-PC, D: di-C7-PC). The symbols used in the ﬁgure are the same as the ones used in Fig. 2 (solid circles: insulin alone, open circles: insulin with 0.5 mM surfactant, solid
squares: insulin with 1 mM surfactant, open squares: insulin with 2 mM surfactant, solid diamonds: insulin with 4 mM surfactant).
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MTT reduction by the cells treated with 100 μM 320-h aged BPI ﬁbrils,
and 4 mM di-C6-PC for 24 h was found to be ∼80% of that of the
control cells. The concentration-dependent protective effect of the
surfactants on cell viability was also detected with di-C7-PC, as
illustrated in Fig. 5B. The cytotoxic effect of the BPI ﬁbril on PC 12 cells
was negatively correlated with increasing di-C7-PC concentration
ranging from 0 to 4 mM. Furthermore, SH-SY5Y cells were protectedTable 2
Estimates of the secondary structural components of bovine insulin in the absence and pre
Incubation
time (h)
Secondary
structure
content
Insulin
by
itself
di-C6-PC
0.5 mM 1 mM
0 α-helix 38% 39% 38%
β-Sheet 16% 17% 18%
Turn 16% 18% 17%
Unordered 30% 26% 27%
320 α-Helix 7% 16% 18%
β-Sheet 41% 33% 32%
Turn 19% 13% 11%
Unordered 33% 38% 39%from the effects of BPI ﬁbril on MTT reduction by addition of di-C6-PC
or di-C7-PC, which was analogous to the protective trend observed in
the PC12 cells (see Fig. 4B). Closer examination of our MTT reduction
results revealed that while comparable inhibitory effects of both
surfactants were apparent at 4 mM, di-C7-PC was evidently more
potent or effective than di-C6-PC at mitigating the cytotoxicity of
100 μM BPI ﬁbrils within the concentration range investigated (see
Fig. 5B, pb0.001, compare with the BFI-only treated cells).sence of amphiphilic surfactants as obtained from CD spectral analyses.
di-C7-PC
2 mM 4 mM 0.5 mM 1 mM 2 mM 4 mM
39% 40% 41% 41% 40% 38%
17% 19% 19% 19% 20% 14%
19% 16% 16% 16% 19% 17%
25% 25% 24% 24% 21% 31%
20% 26% 11% 26% 27% 35%
34% 30% 37% 28% 29% 20%
12% 12% 15% 15% 16% 12%
34% 32% 37% 31% 28% 33%
Fig. 5. (A) The effect of ﬁbrillar insulin concentration on insulin-induced cytotoxicity in
PC12 and SH-SY5Y cells. (B) The inﬂuence of amphiphilic surfactants on PC12 cell and
SH-SY5Y cell viability. The cell viability upon exposure to insulin sample was measured
byMTT reduction. Untreated PC12 or SH-SY5Y cells were exposed to 320-h aged bovine
insulin samples without or with either surfactant at various concentrations (0.5, 1, 2,
and 4 mM) for 24 h at 37 °C in a humidiﬁed 5% CO2 environment. The data are reported
as the percentage of the MTT reduced by the cells incubated with the insulin alone or
insulin with various concentrations of surfactant (di-C6-PC or di-C7-PC). The means±
SD of at least 8 determinations are presented.
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Insulin is a small disulﬁde-containing helical protein hormone
whose normal functions include regulating glucose metabolism,stimulating lipogenesis, and increasing amino acid transport into
cells [35–40]. In vivo, ﬁbrillar insulin-containing deposits have been
previously observed in patients with type II diabetes (insulin-
dependent diabetes) [41,42] and during normal aging [43]. During
the treatment of diabetes, intravenous injection and subcutaneous
infusion of porcine insulin bring about a complication whereby
aggregation at high local concentration of insulin protein occurs, thus
leading to the formation of pathogenic deposition or ﬁbrillation of
insulin at the sites of frequent injections [44–46]. Aggregated form of
insulin becomes therapeutically ineffective, and the injection of such
species is likely to trigger an unwanted/adverse immune response
[47]. In vitro, insulin has been shown to exhibit an increased
propensity for ﬁbrillation upon exposure to conditions that result in
the buildup of partially folded intermediates such as mutation,
addition of co-solvents, acidic pH, elevated temperatures, and
dissolution with organic solvents [12,13,48–50]. In addition, the
ﬁbrillar species of insulin have been shown to be toxic to pancreatic β-
cells [51] and rat pheochromocytoma PC12 cells [34]. Results from
previous investigations suggest that the key driving force for insulin
ﬁbrillation is hydrophobic interaction, which is attributed to the
enhanced exposure of buried tryptophans to solvent [52]. It should be
noted that the aggregation/ﬁbrillation of protein-based drugs such as
insulin has been a limiting factor during themanufacture, puriﬁcation,
storage, and delivery processes in the biopharmaceutical industry
[53–55]. The reasons why bovine insulin was chosen as the model
protein in this study are as follows: (1) bovine insulin and human
insulin exhibit a very similar sequence and structure. (2) There exists
a wealth of data regarding the biochemical and structural properties
of bovine insulin. (3) Bovine insulin has been reported to retain a high
ﬁbril-forming propensity at the acidic pH [47]. (4) Bovine insulin is
available in large quantities at reasonable price. (5) We would like to
test whether the ﬁbrillation of other amyloid-forming proteins (e.g.,
bovine insulin) can be reduced upon exposure to di-C6-PC or di-C7-
PC, which were demonstrated to attenuate Aβ peptide ﬁbrillation
found in our earlier work [11]. (6) Aside from their anti-ﬁbrillogenic
potencies, the effects of di-C6-PC and di-C7-PC on insulin ﬁbril-
elicited cell toxicity were also examined in this research.
A number of researchers have hypothesized that all amyloid-
forming polypeptides, regardless of their primary sequence, may
exhibit the same structure-speciﬁc toxicity via common mechanisms
[4,56–58]. There is a wealth of data demonstrating that amyloids are
cytotoxic when present in an aggregated form containing mature
ﬁbrils, protoﬁbrils, and/or low molecular weight intermediates [59–
61]. Moreover, evidence originating from various studies using cell
culture and animal models shows that the reduction of amyloid
aggregation appears to be beneﬁcial [62,63]. To that end, strategies
that utilize agents to diminish the formation of aggregated species and
the amount of β-sheet structure have been proposed as effective
means to alleviate the pathological effects of amyloids or counteract
the development of amyloidoses [9,10,64].
Molecules or compounds that have been reported to retard or
prevent the aggregation/ﬁbrillation or cytotoxicity of amyloid-
forming proteins include peptides, peptide fragments, peptidomi-
metics (peptidic inhibitors), and non-peptidic small molecules. The
peptidic inhibitors include peptide fragments composed of a recog-
nition sequence [65,66], the compounds containing the β-sheet
breaker peptides in association with the incorporation of proline
[67,68]. Other peptidemolecules that have shown inhibitory potential
towards the aggregation or cytotoxicity of amyloid proteins fall into
the category of small heat shock proteins with molecular chaperones-
like activity [69,70]. A wide range of non-peptidic chemicals or natural
compounds have been shown to be potent inhibitors of the ag-
gregation/ﬁbrillation and/or cytotoxicity induced by amyloid-form-
ing proteins [71–73]. These non-peptidic inhibitory molecules include
the natural or synthetic aromatic phenolic ring-containing polyphe-
nols [10,74]. Molecules such as the sulfonated dye Congo red and
Fig. 6. The inﬂuence of hydrophobicity or amphiphilicity on amyloid ﬁbrialltion of
bovine insulin. Bovine insulin samples were dissolved in hydrochloric acid (pH 2.0) and
incubated at 55 °C during the course of experiment. The extent of ﬁbril formation of
bovine insulin was estimated via ThT ﬂuorescence, and the relative ThT ﬂuorescence
intensity was determined by the ratio of ThT ﬂuorescence of the additive-containing
sample to the maximum ThT ﬂuorescence intensity (the control at 320 h). The CMC
values of Span 20 and Brij 30 were determined to be 25 μM and 4 μM, respectively. The
concentrations of Span 20 or Brij 30 used were above and below the CMC. Data
represent the mean value of at least 5 independent experiments (n≥5). Error bars
represent the standard deviation (SD) of the measurement.
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loid-elicited cytotoxicity by preventing ﬁbrillation or by binding
directly to amyloid ﬁbrils [75,76]. A semisynthetic bactericidal anti-
biotic drug, rifampicin, which is used to treat leprosy and tuberculosis,
and its derivatives are known to exhibit anti-aggregating activity and
reduce toxicity [77,78]. Acridine-based compounds may effectively
reduce aggregation of amyloid proteins [73,79]. Similar effects were
also observed for other low molecular weight compounds [58,80,81].
Thus, these small molecules could provide a basis for the development
of therapeutic for amyloid diseases.
We ﬁrst demonstrated that, in the absence of surfactant, formation
of BPI ﬁbrils does occur when the samples are incubated at pH 2.0 and
55 °C (see Figs. 1 and 3A). We then tested di-C6-PC and di-C7-PC for
their effects on the in vitro ﬁbrillation of BPI. As seen in Figs. 2 and 3B
and C, our experiments showed that di-C6-PC and di-C7-PC
suppressed BPI ﬁbril formation at pH 2.0 and 55 °C as indicated by
reductions in ThT ﬂuorescence intensity and Congo red binding and
by TEM. Our results conﬁrm that the suppressing activity of di-C6-PC
or di-C7-PC against BPI ﬁbrillation does depend upon both the
incubation time and surfactant concentration. Moreover, based on the
results of our spectroscopic analyses, 4 mM di-C7-PC more potently
interferes with the ﬁbril formation of BPI.
It has generally been accepted that a correlation exists between
amyloid ﬁbrillation and secondary structure transitions from disor-
dered random structures or α-helix-rich conformations to predom-
inantly ordered β-sheet structures [7,82,83]. This β-sheet structure
has been found to be associated with insolubility and protease
resistance [83,84]. Here as assessed by CD absorption spectroscopy,
we show in Table 2 that either amphiphilic surfactant may prevent BPI
from adopting β-sheet-rich conformations and may seemingly
mitigate the α-to-β conversion observed in the control. Since the
extent of aggregation/ﬁbrillation was correlated with the β-sheet
content, our results suggest that co-incubation with either surfactant
may result in a decrease in BPI ﬁbril formation. Finally, using the MTT
reduction assay, we conclude that bovine insulin is toxic to two
neuron-like cell lines, PC12 and SH-SY5Y cells, under conditions in
which the protein has been shown to adopt the amyloidogenic form
associated with the β-sheet-rich conformation [85,86] (Figs. 1, 4A,
and 5A, and Table 2).
In order to demonstrate whether hydrophobicity or amphiphilicity
is the contributing factor in the reduction of insulin ﬁbrillation of
insulin by di-C6-PC or di-C7-PC, we have chosen the compounds Span
20 and Brij 30 as negative controls. These two compounds exhibit
comparable hydrophilic lipophilic balance (HLB) values with those of
di-C6-PC or di-C7-PC. We have also conducted a couple of experi-
ments, in which insulin was incubated with these compounds. We
found that, relative to di-C6-PC or di-C7-PC, the said compounds at
concentrations below and above the CMC showed appreciably less
effects on insulin ﬁbrillation under the incubation condition used (as
shown in Fig. 6). Our results suggest that the structural speciﬁcity but
not hydrophobicity or amphiphilicity might exert a major effect on
the attenuated ﬁbril formation observed in the insulin samples with
di-C6-PC or di-C7-PC.
Di-C6-PC and di-C7-PC belong to the family of zwitterionic am-
phiphiles, which is ascribed to the negative charge on the phosphate
group and the positive charge on the nitrogen atom of choline at the
physiological pH [87]. They are also known as the short-chain
phospholipids (six to eight carbons per fatty acyl chain: di-Cn-PC,
n=6–8). Through the electrophoretic mobility measurements, the
isoelectric point for these phospholipids was determined to be ∼6
[88,89], suggesting that the di-C6-PC and di-C7-PC would possess the
positive charge state under our incubation condition (pH 2.0). It is
commonly recognized that various aggregate structures are present in
lipid/phospholipid solutions [90]. In general, while longer chain
phospholipids (≧12 carbons per fatty acyl chain) can form bilayer
when dispersed in aqueous solutions, short-chain phospholipidsexhibit the propensity for forming lipid complex or micellar structure
whose average size depends on the fatty acid chain length when the
concentrations of the short-chain phospholipids are above the critical
micelle concentration (CMC), a key micellar parameter that is closely
correlated with the micelle-forming properties of the surfactant [91].
Evidence indicates that the shortest of the micellar phospholipids,
dihexanoyl-PC (di-C6-PC) micelle, demonstrates no noticeable
growth with increased concentration in the range of 27–360 mM. As
the concentration of diheptanoyl-PC (di-C7-PC) increases, the
addition of methylene group to each chain enhances the growth
and polydispersion property of the resultant micelles [91]. Since CMC
of phospholipids is strongly affected by the temperature, salt
concentration, and pH, it was measured using the surface tensiometry
to characterize the aggregation states of the phospholipids under the
incubation conditions used in our study. As depicted in Fig. 7, the CMC
values for di-C6-PC and di-C7-PC were determined to be ∼10.51±
1.21 mM and ∼2.42±0.32 mM, respectively. We conjecture that the
difference between our CMC values and the ones measured by others
arises from its variation in the incubation conditions [92,93]. TEMwas
also employed to gain information about the aggregate structure/
morphology of di-C6-PC and di-C7-PC in the aqueous solutions. We
observed that the micelles and micellar complexes became the
dominating structure when the concentrations of di-C6-PC or di-C7-
PC went above its CMC (micrographs not shown).
Ample evidence suggests that the membrane environment, which
can be produced by phospholipids or mimicked by surfactants
(sodium dodecyl sulfate (SDS), or dodecyltrimethylammonium
bromide (DTAB)), can have profound impact on the conformation
and stability of proteins [94–96]. Also, lipid and lipid metabolites
present in amyloid deposits have the potential to affect the forma-
tion, morphology, and cytotoxicity of ﬁbrils as well as the involved
assembly pathways [97]. Several investigations indicated that the
formed surfactant micelle helps stabilize protein conformations
[98,99]. In addition, as a general observation from numerous studies
Fig. 7. Surface tension versus surfactant concentration for surfactant solution in the
presence of di-C6-PC (solid circles) or di-C7-PC (open circles) at 55 °C and pH 2.0.
Each surface tension data point represents the average of at least 3 independent
measurements (n≥3).
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concentrated surfactant or phospholipid micelle, which provides a
heterogeneous amphiphilic environment, partially or completely
inhibits ﬁbrillation of amyloid-forming proteins [100–102]. For
instance, Han et al. recently showed that the biosurfactant surfactin
micelle-bound species of Aβ were less or non-ﬁbrillogenic in nature
when the surfactin concentration far exceeded the CMC [103]. How-
ever, there remains a discrepancy on how ﬁbrillar aggregation or
cytotoxicity is inﬂuenced by phospholipid or surfactant at the
concentrations where it existed predominantly in the uncomplexed,
submicellar state. For example, SDS below CMC exhibited the ability
to promote ﬁbrillation of β2-microglobulin [104] and fragment of
short consensus repeat 3 [105]. The rate of apoC-II ﬁbrillation
accompanied by secondary structural alterations was reported to be
accelerated by submicellar levels of phospholipids [106]. Li and
coworkers examined the interaction(s) between Aβ(1–40) and the
cationic gemini surfactant hexamethylene-1,6-bis-(dodecyldimethy-
lammonium bromide) or the single-chain cationic surfactant DTAB
and found that Aβ ﬁbrillation/aggregation may be augmented by the
electrostatic interaction between the Aβ and the surfactant monomer
at the concentration below CMC [107]. Moreover, Aβ peptides were
observed to be toxic to cells upon incubation with submicellar SDS
[108]. On the contrary, submicellar concentrations of some short-
chain phospholipids have been documented to suppress ﬁbril
formation of apoC-II fragment [109]. Also, Wood et al. reported that
hexadecyl-N-methylpiperidinium bromide of concentrations almost
an order of magnitude below its CMC had the ability to inhibit Aβ
ﬁbrillation at pH 5.8 [110].
Using atomic force microscopy and dynamic light scattering
spectroscopy, the addition of di-C6-PC to 125 μM Aβ(1-40) under
acidic condition in 0.1 M HCl may lead to a concentration-dependent
reduction in the length, but not the diameter, of the Aβ ﬁbrils
[82,94,95]. Based on the results of elastic light scattering, a recent
study showed that amphiphilic multi-block copolymers surfactants,
such as poloxamers 108 and 188, may potently reduce aggregation
and improve refolding of bovine serum albumin and hen egg-white
lysozyme with denaturation by heat [111]. Moreover, evidence from
our previous work indicated that di-C6-PC and di-C7-PC display anti-
amyloidogenic and anti-aggregating activities against Aβ underphysiological conditions [11]. Our results revealed that the BPI sample
with 4 mM di-C7-PC (above the CMC, a micelle-forming condition)
had a signiﬁcantly lower level of BPI amyloid ﬁbrillation (∼16.69% of
the control, see Fig. 2B and Table 1) and acquired a secondary
structure similar to that of the native conformation (see Fig. 4D).
However, in the samples containing submicellar concentrations of
phospholipids (below the CMC), in which only free phospholipids
were present, a certain degree of ﬁbrillation inhibition was observed
in the BPI–phospholipid mixtures. A close inspection of the data
indicated that, at the same concentration of surfactants or phospho-
lipids, fewer ﬁbrils were formed in the BPI samples with di-C7-PC
compared with that with di-C6-PC, suggesting that the extent of
ﬁbrillation attenuation was correlated with the difference between
surfactant concentration and its CMC value. In our current work, we
further noted that these amphiphilic surfactants successfully allevi-
ated amyloid-induced cell toxicity (Fig. 5B). It is noteworthy that our
results identify for the ﬁrst time that short-chain phospholipids such
as di-C6-PC or di-C7-PC reduce both the ﬁbrillation and cytotoxicity of
amyloid ﬁbrils.
MTT reduction is commonly regarded as a rapid and sensitive
indicator of cell physiological stress, biological redox state, prolifer-
ation, and amyloid-modulated cytotoxicity [112]. While the extent of
MTT reduction is typically correlatedwith loss of viability, a number of
investigators have found that the decrease of MTT reduction may
occasionally result from exocytosis of MTT from the cells, particularly
in the presence of amyloid protein (e.g., Aβ) [113,114]. In these
reports, however, MTT exocytosis and inhibition of MTT reduction in
neuron-like cells, which are similar to the PC12 and SH-SY5Y cells
used in our work, were closely correlated to cytotoxicity observed
in hippocampal cultures as evaluated by direct visualization and
Trypan blue exclusion [108,109]. Moreover, the practice of verifying
MTT reduction results with Trypan blue exclusion, which measures
changes in membrane permeability associated with loss of cell
viability, has been well characterized in the literature [113,115]. We
also performed the Trypan blue internalization test and revealed that
the BPI ﬁbrillar samples employed in our study led to bona ﬁde cell
death (data not shown). Given these lines of evidence, we believe
that important information pertaining to the cytotoxicity or cell via-
bility can be obtained from our measurements of inhibition of MTT
reduction.
The amphiphilic surfactants or short-chain phospholipids belong
to the subclasses of diacyl glycerophosphocholine (diacyl-GPC) or
lecithin. Of note, the surfactants or short-chain phospholipids used
here (di-C6-PC or ci-C7-PC) that are effective in inhibiting insulin
ﬁbril formation were found to be at the concentrations of 4 mM
(∼1.8 mg/ml), whereas in the human body, the concentration is
slightly lower [24]. The concentration of insulin used in this study is
100 μM, which is 2000000-fold higher than normally perceived in the
body (b50 pM) [116–118]. After our calculation, the resulting
protein/lipid ratio was determined to be 40:1, which is comparable
to the level seen in the other relevant research works [107–111,119].
In conclusion, this work examines how the presence of amphi-
philic surfactants, namely, di-C6-PC and di-C7-PC, inﬂuences in vitro
insulin ﬁbrillation via ThT ﬂuorescence enhancement, Congo red
binding experiments, CD spectroscopy, and TEM. In line with our
previous work, our ﬁndings have demonstrated that both di-C6-PC
and di-C7-PC concentration-dependently decrease β-sheet formation
and aggregation, which are characteristics of BPI amyloid ﬁbril
formation. Furthermore, the presence of these surfactants has also
been shown to prevent cells from the cytotoxic effect of BPI ﬁbrils. The
understanding of the role of phospholipids and their complexes in
amyloid ﬁbrillation can shed light on the modulation of protein
aggregation/ﬁbrillation by lipid in vivo. While the ﬁbrillation of bo-
vine insulin, especially at acidic pH, is rarely observed in vivo and
further experiments are warranted to conclusively determine the
detailed mechanism by which amphiphilic surfactants/short-chain
528 S.S.-S. Wang et al. / Biochimica et Biophysica Acta 1802 (2010) 519–530phospholipids retard amyloid ﬁbrillation, aggregation, and induced-
cytotoxicity derived from bovine insulin, we believe that the results
from the current work are still informative and can provide a model
system for future work in this subject matter. It is noteworthy to
mention that lecithin/phosphatidyl choline is currently being used
as a dietary supplement for liver diseases and Parkinson's disease
[120,121]. Along this line, some of the knowledge gained from our
study indicates that the short-chain phospholipids may also be
applicable as a promising strategy for ameliorating the progression of
diseases such as amyloidoses.Acknowledgment
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